About Cambrex
Cambrex is a Healthcare company based in East Rutherford (United States) founded in 1981, and was acquired by Permira in August 2019. CDMO of complex small molecule APIs, including highly potent APIs. The company has 46 employees. Cambrex has completed 7 acquisitions, including Avista Pharma, Biocatalysis and Halo Pharma. Its website cambrex.com draws about 35 thousand monthly visits. Cambrex offers products and services including Custom API Development, Analytical Testing, and Formulation Development. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its legal entity is Cambrex Corporation.
Company details
Cambrex Corporation provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. They offer APIs, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Their custom development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. Cambrex also develops processes to manufacture drug substances for clients use in toxicology studies, clinical studies and commercial supply. Their range of services include route selection, process and analytical development, process optimization and scale-up, safety assessments and product formulation.
- Headquarters East Rutherford, United States
- Employees 46
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website cambrex.com
- Social LinkedIn X Facebook
- Acquired by Permira (Aug 2019)
- Legal Name Cambrex Corporation
- Annual Revenue$532.09 M (USD)as on Dec 31, 2018
- Net Profit$92.42 M (USD)-10as on Dec 31, 2018
- EBITDA$101.5 M (USD)-30as on Dec 31, 2018
- Investors
- Employee Count46
- Investments & AcquisitionsAvista Pharma
& 6 more
- Acquired byPermira
(Aug 2019)
Products & Services of Cambrex
Cambrex offers a comprehensive portfolio of products and services, including Custom API Development, Analytical Testing, and Formulation Development.
Offers custom development and manufacturing of pharmaceutical APIs for clinical trials.
Provides comprehensive analytical testing for drug stability and impurity identification.
Supports early-phase formulation and clinical trial manufacturing processes.
Investors in Cambrex
Cambrex has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Permira.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in technology, consumer, healthcare, and service sectors. | 1985 | permira.com | London, United Kingdom |
Investor details for Cambrex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cambrex
139 people are tracked at Cambrex (53 in leadership, 86 in team); the tracked headcount is 46.
| Name | Role | Group |
|---|---|---|
Dorothy Donnelly-brienza | Senior Vice President and Chief Human Resources Officer | Leadership |
Samantha M. Hanley | Vice President, General Counsel and Secretary | Leadership |
Robert Green | EVP and CFO | Leadership |
Thomas Loewald | CEO & Board Member | Leadership |
Shaheen Khan | Associate Director, Quality Assurance - Compliance | Leadership |
Anne-Louise Hemdahl | Director Quality Assurance & Quality Control | Leadership |
Craig Durr | Director Of Sales And Product Management | Leadership |
Darryl Hester | Director Of Business Development | Leadership |
Saurabh Chitre | Head Of Solid State Science | Leadership |
Brandon Fincher | President, Early Stage Development & Testing | Leadership |
Frank Ferrante | Chief Mergers & Acquisitions Officer | Leadership |
Todd Brunhammer | Sr. Director, Total Rewards & HR Operations | Leadership |
Ryan Brough | Senior Director Of Laboratory Operations | Leadership |
Jeff Blodgett | Director Of Financial Projects | Leadership |
J. Swaroop Mathen | Senior Director, Chemical Development | Leadership |
Derek Koops | Vice President & General Manager | Leadership |
Jeff Adams | Vp, General Manager | Leadership |
Dan Bowles | Vice President And GM At Cambrex | Leadership |
Andrew Spada | Senior Tax Director | Leadership |
Todd Sprouse | Associate Director, Analytical Services | Leadership |
119 more people are available in the full profile.
Complete people profiles for Cambrex
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cambrex
Cambrex has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include Avista Pharma, Biocatalysis and Halo Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Drug discovery and development service provider | snapdragonchemistry.com | Cambridge, United States | 2014 | Nov 2022 | •••• | |
Stability storage services for pharmaceuticals and medical devices are provided. | q1scientific.com | Waterford, Ireland | 2012 | Jun 2022 | •••• | |
Drug development, manufacturing, and testing services are provided to clients. | avistapharma.com | Durham, United States | 2015 | Nov 2018 | $252M | |
Contract development and manufacturing for pediatric dosage forms are provided. | halopharma.com | Hanover, United States | 2006 | Jul 2018 | $425M | |
Contract services for API discovery, development, and manufacturing are provided. | pharmacore.com | High Point, United States | 2000 | Sep 2016 | $25M | |
Specialty contract development and manufacturing services are offered for pharmaceuticals. | zenara.com | Hyderabad, India | 2004 | Nov 2010 | $20M | |
Small molecule drugs and peptides are manufactured by Biocatalysis. | biocatalysis.com | Germany | 2002 | Mar 2010 | •••• |
Complete acquisition details for Cambrex
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Cambrex
10 dated milestones of Cambrex across 41 years, from founding to its latest funding, stage changes and deals.
- Founded Cambrex is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Biocatalysis.
- Acquisition Acquires Zenara.
- Acquisition Acquires PharmaCore.
- Acquisition Acquires Halo Pharma.
- Acquisition Acquires Avista Pharma.
- Exit Acquired by Permira.
- Acquisition Acquires Q1 Scientific.
- Acquisition Acquires Snapdragon Chemistry.
Web traffic of Cambrex
The website of Cambrex (cambrex.com) receives about 35K visits a month and ranks #883,665 among all websites worldwide, #1,063 in Biotechnology and Pharmaceuticals.
- Monthly visits35K
▲ 28% vs previous month
- Unique visitors11.6K
per month
- Global rank#883,665
among all websites
- Category rank#1,063
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit3.1
- Average visit1 min 11 sec
- DevicesDesktop 29% · Mobile 71%
Websites whose visitors overlap most with Cambrex. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| amriglobal.com | 100% | 680.7K | View details | ||
| amgen.com | 94% | 495.4K | #116,434 | View details | |
careers.jazzpharma.com | careers.jazzpharma.com | 88% | #976,438 | – | |
| insmed.com | 83% | 68.8K | #433,178 | View details | |
| bayer.com | 82% | 1.1M | #52,188 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 27 similar websites and full traffic analytics for Cambrex
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 27 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Cambrex (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cambrex
Complete news archive for Cambrex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cambrex
Cambrex was founded in 1981.
Cambrex is headquartered in East Rutherford, United States. It is registered at East Rutherford, New Jersey, United States.
Cambrex has 46 employees.
Annual revenue of Cambrex is $532.09M as on Dec 31, 2018.
Cambrex Corporation provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. They offer APIs, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Their custom development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. Cambrex also develops processes to manufacture drug substances for clients use in toxicology studies, clinical studies and commercial supply. Their range of services include route selection, process and analytical development, process optimization and scale-up, safety assessments and product formulation.
Cambrex offers Custom API Development, Analytical Testing, and Formulation Development.
Cambrex has made 7 acquisitions, including Avista Pharma, Biocatalysis, and Halo Pharma.
Cambrex has 1 investor. Key investors include Permira.
Cambrex operates through Cambrex Corporation.
Yes. Cambrex was acquired by Permira in August 2019.